Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?
Lipoprotein (a) [Lp(a)] has been recognized as an independent, inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, thus representing a major target of residual CV risk. Currently, no drug has been officially approved for lowering Lp(a) levels,...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2025-05-01
|
| Rangatū: | Pharmaceuticals |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/1424-8247/18/5/753 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|